For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Plasminogen, the proenzyme of the fibrinolytically active enzyme plasmin, is a single chain glycoprotein with a molecular weight of about 90,000-94,000 Da (2). Various isoelectric forms exist and can be separated by means of isoelectric focusing (IEF).
The complete amino acid sequence contains 790 amino acids. Native plasminogen (glu-plasminogen) has a N-terminal glutamic acid group. Partial plasma proteolysis gives rise to a molecule with N-terminal lysine (lysplasminogen).
Currently, the product has obtained the designation of orphan drug by the US Food and Drug Administration (FDA) and by the European Medicines Agency (EMA). Clinical trials are still underway to obtain Marketing Authorization in the United States and in Europe (EU). The report mainly targeting the research status, predicted competitive landscape, market potential and future trends of plasminogen market.
Scope of the Report:
Plasminogen was originally used as an orphan drug for the treatment of congenital plasminogen deficiency, but the researchers found that he had positive effects on wound care and Diabetic Foot Ulcer treatment. And there is hope that the amputation costs and pain of such patients will be greatly reduced. Once FDA certification is available in the Diabetic Foot Ulcer area, it will benefit significantly from the 10 billion USD amputation market.
China's demand is the biggest and the most direct in the entire potential market. The main reason is that China's gradual growth in per capita consumption and has a relatively good medical system. In addition, China has the largest number of people with diabetes in the world. The market demand is obvious.
If it only acts as an orphan drug, it had almost no development prospects and market, with Congenital Plasminogen Deficiency as an example, the global prevalence around 10 thousand people, we expect 2000-3000 of these people may use the drugs, but the income is far less than the R & D expenditure. But the research team is optimistic about its potential use, especially in wound care and Diabetic Foot Ulcer treatment.
The worldwide market for Plasminogen is expected to grow at a CAGR of roughly 6.1% over the next five years, will reach 16200 million US$ in 2024, from 11400 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Plasminogen in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Kedrion
- Prometic
- Genentech (Roche)
- Boehringer Ingelheim
- Kyowa Hakko Kirin
- Omeros Corporation
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Intravenous Injection
- Eye Drops
Market Segment by Applications, can be divided into
- Ligneous Conjunctivitis
- Diabetic Foot
- Wound Healing
- Others
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Plasminogen product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Plasminogen, with price, sales, revenue and global market share of Plasminogen in 2017 and 2018.
Chapter 3, the Plasminogen competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Plasminogen breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Plasminogen market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Plasminogen sales channel, distributors, customers, research findings and conclusion, appendix and data source.